References
- Arnold Jr LJ. Dagan A, Gutheil J, Kaplan NO. Antineoplastic activity of poly(L-lysine) with some ascites tumor cells. Proc Nat Acad Sci USA 1979; 76(7)3246–50
- Bilensoy E, Sarisozen C, Esendağlı G, Doğan AL, Aktaş Y, Şen M, Aydın Mungan N. Intravesical cationic nanoparticles of chitosan and polycaprolactone for the delivery of Mitomycin C to bladder tumors. Int J Pharma 2009; 371(1–2)170–6
- De S, Robinson D. Polymer relationships during preparation of chitosan-alginate and poly-l-lysine-alginate nanospheres. J Control Rel 2003; 89(1)101–12
- Grabnar I, Bogataj M, Mrhar A. Influence of chitosan and polycarbophil on permeation of a model hydrophilic drug into the urinary bladder wall. Int J Pharma 2003; 256(1–2)167–73
- Guha SS, Banerjee R. Intravesical drug delivery: Challenges, current status, opportunities and novel strategies. J Controlled Rel 2010; 148(2)147–59
- Illum L. Chitosan and its use as a pharmaceutical excipient. Pharma Res 1998; 15(9)1326–31
- Kaufman DS. Challenges in the treatment of bladder cancer. Ann Oncol 2006; 17(5)v106–12
- Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 2009; 374(9685)239–49
- Kerec Kos M, Bogataj M, Mrhar A. Enhanced permeability of the urinary bladder wall: The role of polymer charge. Die Pharmazie 2009; 64(4)232–7
- Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, Kiemeney L, Kriegmair M, Montironi R, Murphy WM, et al. Bladder cancer: Epidemiology, staging and grading, and diagnosis. Urology 2005; 66(6) (Suppl. 1)4–34
- Konety BR, Joyce GF, Wise M. Bladder and upper tract urothelial cancer. J Urol 2007; 177(5)1636–45
- Kurth KH, Bouffioux C, Sylvester R, van der Meijden AP, Oosterlinck W, Brausi M. Treatment of superficial bladder tumors: Achievements and needs. The EORTC Genitourinary Group. Eur Urology 2000; 37(Suppl. 3)1–9
- Mingyu C, Kai G, Jiamou L, Yandao G, Nanming Z, Xiufang Z. Surface modification and characterization of chitosan film blended with poly-L-lysine. J Biomater Appl 2004; 19(1)59–75
- Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics. CA: Cancer J Clin 2000; 55(2)74–108
- Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB, Cancer incidence in five continents. IARC Sci Publ, 2002;8(155):1–781
- Qi L, Xu Z. In vivo antitumor activity of chitosan nanoparticles. Bioorg Med Chem Lett 2006; 16(16)4243–5
- Qi L, Xu Z, Jiang X, Hu C, Zou X. Preparation and antibacterial activity of chitosan nanoparticles. Carbohydrate Res 2004; 339(16)2693–700
- Quebbeman EJ, Hoffman NE, Ausman RK, Hamid AA. Stability of mitomycin admixtures. Am J Hospital Pharma 1985; 42(8)1750–4
- Sinha VR, Bansal K, Kaushik R, Kumria R, Trehan A. Poly-epsilon-caprolactone microspheres and nanospheres: An overview. Int J Pharma 2004; 278(1)1–23
- Stolk LM, Fruijtier A, Umans R. Stability after freezing and thawing of solutions of mitomycin C in plastic minibags for intravesical use. Pharma Weekblad. Scientific Edition 1986; 8(6)286–8
- Takeuchi H, Yamamoto H, Kawashima Y. Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv Drug Del Rev 2001; 47(1)39–54
- Tammela T, Wein AJ, Monson FC, Levin RM. Urothelial permeability of the isolated whole bladder. Neurourol Urodyn 1993; 12(1)39–47
- Tolley DA, Parmar MK, Grigor KM, Lallemand G, Benyon LL, Fellows ve diğerleri. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: A further report with 7 years of follow up. J Urol 1996; 155(4)1233–8
- Yang X-X, Chen J-H, Liu S-T, Guo D, Zeng X-X. Polybutylcyanoacrylate nanoparticles as a carrier for mitomycin C in rabbits bearing VX2-liver tumor. Regulatory Toxicol Pharmacol 2006; 46: 211–17
- Xu Y, Du Y. Effect of molecular structure of chitosan on protein delivery properties of chitosan nanoparticles. Int J Pharma 2003; 250(1)215–26